Navigation

Exploratory work of bevacizumab in eye conditions

The Department of Health has asked NICE to explore with stakeholders what value we can add in advising the NHS on the clinical and cost effectiveness of Avastin (bevacizumab) to treat wet age-related macular degeneration, the leading cause of blindness in the UK, and other conditions affecting the eye.

Topic

Exploratory work of bevacizumab in eye conditions

Consultation on briefing document and provisional list of stakeholders

02 June 2010 - 30 June 2010

Exploratory workshop

13 July 2010 (morning meeting) in Manchester

Enquiries to:

Jenniffer Alty

Consultation document(s)

Scoping report commissioned by the NIHR HTA Programme (produced by Southampton Health Technology Assessments Centre)

NICE report on findings from the exploratory work regarding the use of bevacizumab in the treatment of wet age-related macular degeneration and other eye conditions

This page was last updated: 06 December 2010

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.